Establishment and Validation of Competitive Counterflow as a Method To Detect Substrates of the Organic Anion Transporting Polypeptide 2B1
The organic anion transporting polypeptide (OATP) 2B1 is ubiquitously expressed and known to facilitate cellular entry. It is widely accepted that transport proteins play a pivotal role in pharmacokinetics. Consequently, testing for interaction with drug transporters became an important part in the...
Uloženo v:
| Vydáno v: | Molecular pharmaceutics Ročník 15; číslo 12; s. 5501 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
03.12.2018
|
| Témata: | |
| ISSN: | 1543-8392, 1543-8392 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The organic anion transporting polypeptide (OATP) 2B1 is ubiquitously expressed and known to facilitate cellular entry. It is widely accepted that transport proteins play a pivotal role in pharmacokinetics. Consequently, testing for interaction with drug transporters became an important part in the assessment of new molecular entities in order to predict and prevent drug-drug interactions. Recently, competitive counterflow (CCF), an indirect method allowing the identification of substrates, was successfully applied to the organic cation transporter 2. It was the aim of this study to test whether CCF can be used to identify substrates of OATP2B1. A protocol for CCF experiments using estrone 3-sulfate (E
S) as the driven compound in expression-verified MDCKII-OATP2B1 cells was established. The protocol was tested using a substance library, which was prior screened for inhibition of OATP2B1-mediated transport accounting for both E
S-binding sites. In CCF experiments, all previously reported OATP2B1 substrates significantly reduced the amount of E
S in equilibrium, classifying them as substrates. In addition, we identified and verified novel substrates of OATP2B1, namely, astemizole and domperidone. Results of the CCF were complemented with cytotoxicity assays or cell-based reporter gene assays to validate the finding of etoposide and teniposide or hyperforin being substrates of OATP2B1, respectively. Our study indicates that the method of CCF can be used to identify substrates of OATP2B1, irrespective, whether interacting with binding site A or A and B, but is limited by solubility issues or the amount of transporter that is expressed in the used cellular system. |
|---|---|
| AbstractList | The organic anion transporting polypeptide (OATP) 2B1 is ubiquitously expressed and known to facilitate cellular entry. It is widely accepted that transport proteins play a pivotal role in pharmacokinetics. Consequently, testing for interaction with drug transporters became an important part in the assessment of new molecular entities in order to predict and prevent drug-drug interactions. Recently, competitive counterflow (CCF), an indirect method allowing the identification of substrates, was successfully applied to the organic cation transporter 2. It was the aim of this study to test whether CCF can be used to identify substrates of OATP2B1. A protocol for CCF experiments using estrone 3-sulfate (E1S) as the driven compound in expression-verified MDCKII-OATP2B1 cells was established. The protocol was tested using a substance library, which was prior screened for inhibition of OATP2B1-mediated transport accounting for both E1S-binding sites. In CCF experiments, all previously reported OATP2B1 substrates significantly reduced the amount of E1S in equilibrium, classifying them as substrates. In addition, we identified and verified novel substrates of OATP2B1, namely, astemizole and domperidone. Results of the CCF were complemented with cytotoxicity assays or cell-based reporter gene assays to validate the finding of etoposide and teniposide or hyperforin being substrates of OATP2B1, respectively. Our study indicates that the method of CCF can be used to identify substrates of OATP2B1, irrespective, whether interacting with binding site A or A and B, but is limited by solubility issues or the amount of transporter that is expressed in the used cellular system.The organic anion transporting polypeptide (OATP) 2B1 is ubiquitously expressed and known to facilitate cellular entry. It is widely accepted that transport proteins play a pivotal role in pharmacokinetics. Consequently, testing for interaction with drug transporters became an important part in the assessment of new molecular entities in order to predict and prevent drug-drug interactions. Recently, competitive counterflow (CCF), an indirect method allowing the identification of substrates, was successfully applied to the organic cation transporter 2. It was the aim of this study to test whether CCF can be used to identify substrates of OATP2B1. A protocol for CCF experiments using estrone 3-sulfate (E1S) as the driven compound in expression-verified MDCKII-OATP2B1 cells was established. The protocol was tested using a substance library, which was prior screened for inhibition of OATP2B1-mediated transport accounting for both E1S-binding sites. In CCF experiments, all previously reported OATP2B1 substrates significantly reduced the amount of E1S in equilibrium, classifying them as substrates. In addition, we identified and verified novel substrates of OATP2B1, namely, astemizole and domperidone. Results of the CCF were complemented with cytotoxicity assays or cell-based reporter gene assays to validate the finding of etoposide and teniposide or hyperforin being substrates of OATP2B1, respectively. Our study indicates that the method of CCF can be used to identify substrates of OATP2B1, irrespective, whether interacting with binding site A or A and B, but is limited by solubility issues or the amount of transporter that is expressed in the used cellular system. The organic anion transporting polypeptide (OATP) 2B1 is ubiquitously expressed and known to facilitate cellular entry. It is widely accepted that transport proteins play a pivotal role in pharmacokinetics. Consequently, testing for interaction with drug transporters became an important part in the assessment of new molecular entities in order to predict and prevent drug-drug interactions. Recently, competitive counterflow (CCF), an indirect method allowing the identification of substrates, was successfully applied to the organic cation transporter 2. It was the aim of this study to test whether CCF can be used to identify substrates of OATP2B1. A protocol for CCF experiments using estrone 3-sulfate (E S) as the driven compound in expression-verified MDCKII-OATP2B1 cells was established. The protocol was tested using a substance library, which was prior screened for inhibition of OATP2B1-mediated transport accounting for both E S-binding sites. In CCF experiments, all previously reported OATP2B1 substrates significantly reduced the amount of E S in equilibrium, classifying them as substrates. In addition, we identified and verified novel substrates of OATP2B1, namely, astemizole and domperidone. Results of the CCF were complemented with cytotoxicity assays or cell-based reporter gene assays to validate the finding of etoposide and teniposide or hyperforin being substrates of OATP2B1, respectively. Our study indicates that the method of CCF can be used to identify substrates of OATP2B1, irrespective, whether interacting with binding site A or A and B, but is limited by solubility issues or the amount of transporter that is expressed in the used cellular system. |
| Author | Meyer Zu Schwabedissen, Henriette E Schäfer, Anima M Bock, Thomas |
| Author_xml | – sequence: 1 givenname: Anima M surname: Schäfer fullname: Schäfer, Anima M organization: Biopharmacy, Department Pharmaceutical Sciences , University of Basel , 4056 Basel , Switzerland – sequence: 2 givenname: Thomas surname: Bock fullname: Bock, Thomas organization: Proteomics Core Facility, Biozentrum , University of Basel , 4056 Basel , Switzerland – sequence: 3 givenname: Henriette E orcidid: 0000-0003-0458-4579 surname: Meyer Zu Schwabedissen fullname: Meyer Zu Schwabedissen, Henriette E organization: Biopharmacy, Department Pharmaceutical Sciences , University of Basel , 4056 Basel , Switzerland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30380886$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkLtOxDAURC0E4v0LyHQ0u9jOw0kJy_KQQCCx0K5u7BvWKLGDfQPiF_hqQIBENaeYOcXssHUfPDJ2KMVUCiWPwaRpH7phBbEHgyNNq0aIMpNrbFsWeTapslqt_-MttpPSsxAqL1S2ybYykVWiqspt9jFPBE3n0qpHTxy85Y_QOQvkgueh5bPQD0iO3Ct-8egJY9uFNw6JA79BWgXLF4GfIaEhfj82iSIQpu8trZDfxifwzvAT_y1cRPBpCJGcf-J3oXsfcCBnkatTucc2WugS7v_mLns4ny9ml5Pr24ur2cn1BHJV08RUFkCXWJm6QChyXTe5FhbytgZAhNLIrC2ggVyXWhmrpATRoLCy0caoUu2yox_vEMPLiImWvUsGuw48hjEtlVS6zrUuq6_qwW91bHq0yyG6HuL78u8_9Ql0XHv5 |
| CitedBy_id | crossref_primary_10_3390_pharmaceutics13060834 crossref_primary_10_1124_mol_118_114066 crossref_primary_10_1007_s12035_025_04807_7 crossref_primary_10_1016_j_envpol_2023_121882 crossref_primary_10_1007_s13318_024_00902_7 crossref_primary_10_1158_2767_9764_CRC_24_0332 crossref_primary_10_1016_j_dmpk_2021_100418 crossref_primary_10_1002_ptr_8063 crossref_primary_10_1096_fj_202300530RR crossref_primary_10_1111_jnc_16125 crossref_primary_10_1096_fj_202100648R crossref_primary_10_1007_s11095_020_02831_x crossref_primary_10_1111_bph_14936 crossref_primary_10_1016_j_taap_2021_115704 crossref_primary_10_3390_molecules27206815 crossref_primary_10_3390_ijms222312926 crossref_primary_10_3390_cancers12082263 crossref_primary_10_1124_dmd_124_001686 crossref_primary_10_3390_metabo13010045 crossref_primary_10_1016_j_jpba_2023_115716 crossref_primary_10_1111_bph_16205 crossref_primary_10_1016_j_dmd_2025_100069 crossref_primary_10_1080_00498254_2019_1629043 crossref_primary_10_1055_a_1305_3936 crossref_primary_10_1016_j_bcp_2023_115448 crossref_primary_10_1016_j_bcp_2021_114534 crossref_primary_10_3389_fphys_2022_969363 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1021/acs.molpharmaceut.8b00631 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1543-8392 |
| ExternalDocumentID | 30380886 |
| Genre | Validation Studies Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -~X 123 4.4 53G 55A 5VS 7~N AABXI ABBLG ABJNI ABLBI ABMVS ABQRX ABUCX ACGFS ACS ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CGR CS3 CUPRZ CUY CVF DU5 EBS ECM ED~ EIF EJD F5P GGK GNL H~9 IH9 JG~ NPM P2P RNS ROL UI2 VF5 VG9 W1F 7X8 |
| ID | FETCH-LOGICAL-a429t-c8daa76e8c95ea5479b470da4f9aaeea6c13f5aba47672cd211a0be0d1b7cc262 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 29 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000452344600007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1543-8392 |
| IngestDate | Thu Oct 02 09:48:48 EDT 2025 Mon Jul 21 06:00:06 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | organic anion transport competitive counterflow drug transporter substrate identification OATP2B1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a429t-c8daa76e8c95ea5479b470da4f9aaeea6c13f5aba47672cd211a0be0d1b7cc262 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-0458-4579 |
| PMID | 30380886 |
| PQID | 2127947768 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2127947768 pubmed_primary_30380886 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-12-03 |
| PublicationDateYYYYMMDD | 2018-12-03 |
| PublicationDate_xml | – month: 12 year: 2018 text: 2018-12-03 day: 03 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular pharmaceutics |
| PublicationTitleAlternate | Mol Pharm |
| PublicationYear | 2018 |
| SSID | ssj0024523 |
| Score | 2.384178 |
| Snippet | The organic anion transporting polypeptide (OATP) 2B1 is ubiquitously expressed and known to facilitate cellular entry. It is widely accepted that transport... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 5501 |
| SubjectTerms | Animals Chemistry, Pharmaceutical - instrumentation Chemistry, Pharmaceutical - methods Dogs Drug Interactions Estrone - analogs & derivatives Estrone - pharmacokinetics HeLa Cells Hep G2 Cells Humans Madin Darby Canine Kidney Cells Organic Anion Transporters - genetics Organic Anion Transporters - metabolism Recombinant Proteins - genetics Recombinant Proteins - metabolism Small Molecule Libraries - pharmacokinetics Substrate Specificity |
| Title | Establishment and Validation of Competitive Counterflow as a Method To Detect Substrates of the Organic Anion Transporting Polypeptide 2B1 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30380886 https://www.proquest.com/docview/2127947768 |
| Volume | 15 |
| WOSCitedRecordID | wos000452344600007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagrRCXAgVKy0NTCfVUtxvHsZ0TKn2IA13lsKC9rcYvCalNCilU_Qv91R07KXvhgNRLbrYszWTm84zn-xj7iJWMAkXFRawllwIVN04V3LlaFMFg9AO7_lc9nZr5vG7Ggls_Pqu8j4k5UPvOpRr5QWIir6UmdPzp8idPqlGpuzpKaDxmqyVBmeTVem6WXHtVlncjlFDyBASesJ2BrKA4QNfvX3RpnHUsHO-b5ICj1tw_kWbOOKfPHnrW52x9xJpwODjHC_YotBtstxkOc7MHs-XsVb8Hu9AsaaxvXrLbEwKOuUaVCoiArYfvBNoHDSboIhxlyJ3fHkEabU-C1-fdNWAPCGdZmRpmHRyH1KeAFKEyE26f1hLshGEM1MFhmzb8y7JOuRSa7pzuxxTNfADxuXjFvp2ezI6-8FG5gSPltyvujEfUKhhXV4HcQddW6olHGWvEEFC5oowVWpRaaeE83UJxYsPEF1Y7J5R4zVbarg1vGISgrYpoYxmtJDyCWtKGUpde1dZKs8V27m2woD8jtTuwDd3vfrG0whbbHAy5uBwoPBaUuA3FV7X9H6vfsqeEkkx-w1K-Y6uR4kJ4z9bcn6sf_a8P2eXoO23O7gDfeeaI |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Establishment+and+Validation+of+Competitive+Counterflow+as+a+Method+To+Detect+Substrates+of+the+Organic+Anion+Transporting+Polypeptide+2B1&rft.jtitle=Molecular+pharmaceutics&rft.au=Sch%C3%A4fer%2C+Anima+M&rft.au=Bock%2C+Thomas&rft.au=Meyer+Zu+Schwabedissen%2C+Henriette+E&rft.date=2018-12-03&rft.issn=1543-8392&rft.eissn=1543-8392&rft.volume=15&rft.issue=12&rft.spage=5501&rft_id=info:doi/10.1021%2Facs.molpharmaceut.8b00631&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8392&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8392&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8392&client=summon |